Chemo, immunotherapy, and radiation for lymph node-positive triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer that has spread to the lymph nodes.
- You must be at least 18 years old.
- You must be in good enough physical condition to undergo treatment (ECOG or Karnofsky performance score 0 or 1).
- You cannot have an active infection that requires treatment.
- You cannot be pregnant or breastfeeding.
- You cannot have had prior radiation to the same breast, chest wall, or thoracic area.
- You cannot have had prior invasive breast cancer on the same side, cancer in the opposite breast, or another invasive cancer that has been active in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.